Study of Blinatumomab and Asciminib for Ph+ ALL
This study is testing a combination of two drugs, blinatumomab and asciminib, for people with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). Blinatumomab is given by infusion, and asciminib is taken by mouth. The study aims to see if this combination can help control Ph+ ALL. You might be able to join if you are 18 or older and have newly diagnosed or minimally treated Ph+ ALL, especially if intensive chemotherapy isn't suitable for you. The main goal is to understand the safety of the treatment and how well it works to reduce the amount of leukemia cells in your body. This study plans to enroll 40 participants, but its current recruitment status is unclear.
- Study design
- This is an interventional study, meaning participants will receive specific treatments. It is designed to evaluate safety and effectiveness in up to 40 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your safety and any side effects will be monitored through study completion, which is an average of one year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
At a glance
Conditions
Where it's being run
2 sites across 2 statesStudy leadership
- Nicholas Short, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Safety and adverse events (AEs)Through study completion; an average of 1 year.
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0